Table 2.
Correlation between Trx1 level and clinicopathological characteristics in breast cancer patients and women without cancer
| Correlation between Trx1 level and age in breast cancer patients and women without cancer | |||||
| Variable | Age | Trx1 (95% CI) | No. | % | P Value |
| Women without cancer | 30s | 3.16(1.16 to 5.16) | 3 | 2.6 | 0.6689 |
| (n = 114) | 40s | 5.99(4.06 to 7.91) | 14 | 12.3 | |
| 50s | 6.31(4.67 to 7.95) | 30 | 26.3 | ||
| 60s | 4.84(3.55 to 6.12) | 36 | 31.6 | ||
| 70s | 5.29(3.44 to 7.15( | 29 | 25.4 | ||
| 80s | 5.25(NA) | 2 | 1.8 | ||
| Breast cancer patients | 30s | 22.60 (16.0 to 29.2) | 7 | 6.6 | 0.705 |
| (n = 106) | 40s | 22.85 (20.5 to 25.2) | 47 | 44.3 | |
| 50s | 20.75 (19.22 to 22.27) | 42 | 39.6 | ||
| 60s | 22.44 (17.0 to 27.82) | 10 | 9.4 | ||
| Correlation between Trx1 level and clinicopathological characteristics in breast cancer patientsa | |||||
| Variable | Trx1(95% CI) | No. (n = 106) | % | P Value | |
| Histologic grade | 1 | 22.08 (19.61 to 24.55) | 24 | 22.6 | 0.8422 |
| 2 | 21.19 (19.54 to 22.84) | 51 | 48.1 | ||
| 3 | 23.14 (19.95 to 26.32) | 31 | 29.3 | ||
| Histologic subtypes | DCIS | 22.25 (NA) | 2 | 1.9 | 0.5083 |
| IDC | 22.00 (20.54 to 23.45) | 92 | 86.8 | ||
| ILC | 24.63 (19.78 to 29.48) | 5 | 4.7 | ||
| MC | 20.41 (13.78 to 27.03) | 5 | 4.7 | ||
| IMPC | 19.07 (NA) | 1 | 0.9 | ||
| ITC | 15.55 (NA) | 1 | 0.9 | ||
| Molecular subtypes | Luminal A | 20.18 (18.44 to 21.92) | 47 | 44.3 | 0.1043 |
| Luminal B | 23.31 (20.69 to 25.92) | 37 | 34.9 | ||
| TNBC | 24.45 (20.92 to 27.98) | 13 | 12.3 | ||
| HER2-enriched | 22.15 (17.43 to 26.87) | 9 | 8.5 | ||
| TNM Stage | 0 | 22.25 (NA) | 2 | 1.9 | 0.4383 |
| 1 | 21.64 (19.48 to 23.8) | 37 | 35 | ||
| 2 | 21.94 (20.22 to 23.66) | 50 | 47.2 | ||
| 3 | 21.86 (16.46 to 27.26) | 15 | 14.2 | ||
| 4 | 28.97 (NA) | 2 | 1.9 | ||
| Ki67 | < 15% | 21.52 (20.06 to 22.97) | 49 | 46.2 | 0.7368 |
| ≥15% | 22.34 (20.22 to 24.47) | 57 | 53.8 | ||
a The clinical information of breast cancer patients was classified according to breast cancer stage, histological grade, proliferation activity, type, and molecular subtype. DCIS ductal carcinoma in situ, IDC invasive lobular carcinoma, MC mucinous carcinoma, IMPC invasive micropapillary carcinoma, ITC invasive tubular carcinoma, TNBC triple-negative breast cancer